Skip to content

© 2026 ChronopinRestaurants About Privacy policy Terms of use Contact

Search

Johnson & Johnson: upcoming dates · Chronopin

Chronopin
/
Companies
/
Johnson & Johnson

Johnson & Johnson: upcoming dates

Upcoming dates: 3 · All pins: 12

Next: J&J Third-Quarter 2026 Results and Investor Call, October 13, 2026.

Johnson & Johnson (J&J) is an American multinational pharmaceutical, biotechnology, and medical technologies corporation headquartered in New Brunswick, New Jersey. The company is ranked No. 42 on the 2026 Fortune 500 list of the largest United States corporations.

All Johnson & Johnson pins in search Wikipedia Website

Upcoming

Finance09/23/2026@HealthDesk
J&J Third-Quarter 2026 Results and Investor Call
Johnson & Johnson World Headquarters, 1 Johnson and Johnson Plaza, New Brunswick, New Jersey 08933, United StatesJohnson & Johnson
Starts 10/13/2026 12:30PM UTCSCHEDULEDDate confidence: SCHEDULEDGiven as scheduledHow firmly the source words the date: confirmed, scheduled, estimated, delayed or unverified.Show all SCHEDULED pins73% CONFIDENCEOverall confidence: 73%How well the pin's source and references back up its dates.Weighted average of how firmly 4 references, the source included, support the pin's start and end times; a reference counts half as much for every 180 days older than the newestShow all pins from 50% to 74% confidencein 6 days
Scheduled by J&J's 31 August release: it "will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday, October 13th to review third-quarter results" and "The press release will be available at approximately 6:45 a.m. (Eastern Time) the morning of the conference call"; 8:30 a.m. EDT is 12:30 UTC.^[1]
Johnson & Johnson releases its third-quarter 2026 results at about 6:45 a.m. Eastern on Tuesday 13 October and reviews them on an 8:30 a.m. investor call hosted by CEO Joaquin Duato and CFO Joseph Wolk.

Related tags

J&J13
Health269
Business767
Finance449
Guidance44
Earnings269
Cancer9
Webcast10
Investor Day14
Phase 325
Acquisition

Business09/23/2026@HealthDesk

J&J Enterprise Business Review (Investor Day)

Johnson & Johnson World Headquarters, 1 Johnson and Johnson Plaza, New Brunswick, New Jersey 08933, United States

Johnson & Johnson

J&J Enterprise Business Review (Investor Day)

J&J Enterprise Business Review (Investor Day)

J&J Enterprise Business Review (Investor Day)

Starts 12/08/2026SCHEDULEDDate confidence: SCHEDULEDGiven as scheduledHow firmly the source words the date: confirmed, scheduled, estimated, delayed or unverified.Show all SCHEDULED pins85% CONFIDENCEOverall confidence: 85%How well the pin's source and references back up its dates.Weighted average of how firmly 5 references, the source included, support the pin's start and end times; a reference counts half as much for every 180 days older than the newestShow all pins at 75% confidence or betterin 62 days

J&J set the date itself: CFO Joseph Wolk said on the 15 July Q2 call "We look forward to sharing more on strategy, growth catalysts and a longer-term outlook at our Enterprise business review on December 8", and the source^[1] reports he "expects to present stronger growth expectations at its Dec. 8 investor day"; no time or venue has been announced, so the pin sits at J&J's headquarters as an all-day date.

Johnson & Johnson holds its first enterprise business review since December 2023, where CFO Joseph Wolk says it will set out growth above its 5% to 7% long-term target, with a clear line of sight to double digits by the end of the decade.

1

Health09/23/2026@HealthDesk

DePuy Synthes Separates From Johnson & Johnson

325 Paramount Drive, Raynham, Massachusetts 02767, United States

Johnson & Johnson

DePuy Synthes Separates From Johnson & Johnson

DePuy Synthes Separates From Johnson & Johnson

DePuy Synthes Separates From Johnson & Johnson

Starts 07/01/2027ESTIMATEDDate confidence: ESTIMATEDA target, not a fixed dateHow firmly the source words the date: confirmed, scheduled, estimated, delayed or unverified.Show all ESTIMATED pins71% CONFIDENCEOverall confidence: 71%How well the pin's source and references back up its dates.Weighted average of how firmly 5 references, the source included, support the pin's start and end times; a reference counts half as much for every 180 days older than the newestShow all pins from 50% to 74% confidencein 267 days

J&J's 10-Q for the quarter to 28 June 2026 targets "completion within 18 to 24 months after the initial announcement" of 14 October 2025 (mid-April to mid-October 2027), and CFO Joseph Wolk said in July that J&J "is on track for a mid-2027 separation" (Bloomberg); "mid-2027" is read as the middle of the year, 1 July 2027, which sits inside that window.^[1]

Johnson & Johnson's orthopaedics business is due to leave the group as DePuy Synthes - by tax-free spinoff or by sale, with Apollo in talks at about $20 billion - and J&J says it is on track for a mid-2027 separation.

2

Recent

Health09/23/2026@HealthDesk
Caplyta Hits Its Goal in a Phase 3 Bipolar Mania Trial
Titusville, Hopewell Township, Mercer County, New Jersey, United StatesJohnson & Johnson
Starts 09/21/2026 12:00PM UTCCONFIRMEDDate confidence: CONFIRMEDStated as firmHow firmly the source words the date: confirmed, scheduled, estimated, delayed or unverified.Show all CONFIRMED pins85% CONFIDENCEOverall confidence: 85%How well the pin's source and references back up its dates.Weighted average of how firmly 4 references, the source included, support the pin's start and end times; a reference counts half as much for every 180 days older than the newestShow all pins at 75% confidence or better16 days ago
The release is datelined "TITUSVILLE, N.J. (September 21, 2026) - Johnson & Johnson (NYSE: JNJ^[1][4]) today announced positive topline results from the pivotal Phase 3 study", and its PR Newswire copy is timestamped "Sep 21, 2026, 08:00 ET" (12:00 UTC).
Johnson & Johnson reported positive topline results from Study 451: once-daily Caplyta (lumateperone) 42 mg cut manic symptoms in bipolar I disorder by 4.8 YMRS points more than placebo at week 3, with a significant effect from day 3.
Business09/23/2026@HealthDesk
Apollo in Talks to Buy J&J's DePuy Synthes for About $20 Billion
Johnson & Johnson World Headquarters, 1 Johnson and Johnson Plaza, New Brunswick, New Jersey 08933, United StatesJohnson & Johnson
Starts 09/11/2026CONFIRMEDDate confidence: CONFIRMEDStated as firmHow firmly the source words the date: confirmed, scheduled, estimated, delayed or unverified.Show all CONFIRMED pins82% CONFIDENCEOverall confidence: 82%How well the pin's source and references back up its dates.Weighted average of how firmly 5 references, the source included, support the pin's start and end times; a reference counts half as much for every 180 days older than the newestShow all pins at 75% confidence or better26 days ago
The disclosure is Bloomberg's report, dated "September 11, 2026" (Yahoo's^[1][2][5] syndicated copy went up at 22:26 UTC and quotes Friday's closing share prices); Reuters' write-up the same evening says "Bloomberg News reported on Friday", and Quartz's 14 September story is a follow-up, so the pin is the all-day 11 September.
Bloomberg reported that Apollo Global Management is in talks to buy DePuy Synthes, J&J's $9.3 billion-a-year orthopaedics unit, at a value close to $20 billion, with a deal possible within weeks though J&J could still spin the unit off instead.
$20B
Business09/23/2026@HealthDesk
J&J Completes Its $1 Billion Acquisition of Firefly Bio
South San Francisco, San Mateo County, California, United StatesJohnson & Johnson
Starts 07/29/2026CONFIRMEDDate confidence: CONFIRMEDStated as firmHow firmly the source words the date: confirmed, scheduled, estimated, delayed or unverified.Show all CONFIRMED pins87% CONFIDENCEOverall confidence: 87%How well the pin's source and references back up its dates.Weighted average of how firmly 4 references, the source included, support the pin's start and end times; a reference counts half as much for every 180 days older than the newestShow all pins at 75% confidence or better70 days ago
"NEW BRUNSWICK, NJ (July 29, 2026) - Johnson & Johnson (NYSE: JNJ^[1][3]) today announced the successful completion of its acquisition of Firefly Bio, Inc. ... for $1 billion in cash"; the 8-K furnishing it gives "Date of report (Date of earliest event reported): July 29, 2026".
Johnson & Johnson closed its $1 billion cash purchase of Firefly Bio, the South San Francisco biotech behind the Firelink degrader antibody conjugate platform for KRAS-driven and other hard-to-treat solid tumours.
$1B
Law09/23/2026@HealthDesk
J&J Proposes $5.5 Billion Deal to Settle 76,000 Ovarian Cancer Talc Claims
Johnson & Johnson World Headquarters, 1 Johnson and Johnson Plaza, New Brunswick, New Jersey 08933, United StatesJohnson & Johnson
Starts 07/27/2026 10:15PM UTCCONFIRMEDDate confidence: CONFIRMEDStated as firmHow firmly the source words the date: confirmed, scheduled, estimated, delayed or unverified.Show all CONFIRMED pins82% CONFIDENCEOverall confidence: 82%How well the pin's source and references back up its dates.Weighted average of how firmly 6 references, the source included, support the pin's start and end times; a reference counts half as much for every 180 days older than the newestShow all pins at 75% confidence or better72 days ago
J&J's release is datelined "New Brunswick, N.J. - JULY 27, 2026 - Johnson & Johnson (NYSE: JNJ^[1]) ... today announced", and the copy filed as Exhibit 99.1 to its 8-K is marked "FOR RELEASE AT 6:15PM ET", 22:15 UTC in EDT.
Johnson & Johnson announced a proposed resolution of its remaining ovarian talc litigation, about 76,000 claims, with a $5.5 billion commitment paid per claim - no more than $3 billion in 2027 and nothing more before 2028 - if at least 95% of claimants take part.
$5.5B
Finance09/23/2026@HealthDesk
J&J Q2 2026 Results: $25.3B Sales, 2026 Outlook Raised
Johnson & Johnson World Headquarters, 1 Johnson and Johnson Plaza, New Brunswick, New Jersey 08933, United StatesJohnson & Johnson
Starts 07/15/2026 12:30PM UTCCONFIRMEDDate confidence: CONFIRMEDStated as firmHow firmly the source words the date: confirmed, scheduled, estimated, delayed or unverified.Show all CONFIRMED pins83% CONFIDENCEOverall confidence: 83%How well the pin's source and references back up its dates.Weighted average of how firmly 6 references, the source included, support the pin's start and end times; a reference counts half as much for every 180 days older than the newestShow all pins at 75% confidence or better84 days ago
Confirmed by J&J's release dated "New Brunswick, N.J. (July 15, 2026)", which says it "will conduct a conference call with investors to discuss this earnings release today at 8:30 a.m., Eastern Time" (12:30 UTC; the edited transcript is stamped "JULY 15, 2026 / 12:30PM GMT").^[1]
Johnson & Johnson reported second-quarter sales of $25.3 billion, up 6.6%, and adjusted EPS of $2.90, and raised its 2026 outlook to about $101.1 billion in sales and $11.68 adjusted EPS at the midpoint.
Health09/23/2026@HealthDesk
FDA Approves Icotyde, the First Oral IL-23 Receptor Pill for Psoriasis
Spring House, Lower Gwynedd Township, Montgomery County, Pennsylvania, 19477, United StatesJohnson & Johnson
Starts 03/17/2026 8:12PM UTCCONFIRMEDDate confidence: CONFIRMEDStated as firmHow firmly the source words the date: confirmed, scheduled, estimated, delayed or unverified.Show all CONFIRMED pins88% CONFIDENCEOverall confidence: 88%How well the pin's source and references back up its dates.Weighted average of how firmly 4 references, the source included, support the pin's start and end times; a reference counts half as much for every 180 days older than the newestShow all pins at 75% confidence or better204 days ago
The FDA's^[4] approval letter for NDA 220149 says the application "is approved, effective on the date of this letter" and was electronically signed "03/17/2026 04:12:23 PM" (Eastern, 20:12 UTC); J&J announced it the next morning: "SPRING HOUSE, Pa. (March 18, 2026) - ... announced today that the U.S. Food and Drug Administration (FDA) has approved ICOTYDE".
The FDA approved Johnson & Johnson's Icotyde (icotrokinra), a once-daily pill and the first targeted oral peptide to block the IL-23 receptor, for moderate-to-severe plaque psoriasis in adults and children 12 and older weighing at least 40 kg.
Health09/23/2026@HealthDesk
J&J Picks Wilson, North Carolina for a Second 500-Job Drug Plant
Wilson, Wilson County, North Carolina, United StatesJohnson & Johnson
Starts 01/09/2026CONFIRMEDDate confidence: CONFIRMEDStated as firmHow firmly the source words the date: confirmed, scheduled, estimated, delayed or unverified.Show all CONFIRMED pins87% CONFIDENCEOverall confidence: 87%How well the pin's source and references back up its dates.Weighted average of how firmly 6 references, the source included, support the pin's start and end times; a reference counts half as much for every 180 days older than the newestShow all pins at 75% confidence or better271 days ago
The governor's release is dated "Friday, January 9, 2026" and begins "Today Governor Josh Stein announced Johnson & Johnson ... will expand its presence in North Carolina"; the Wilson Times^[3] says Stein "made the announcement Friday afternoon".
North Carolina Governor Josh Stein announced that Johnson & Johnson will build a second multibillion-dollar plant in Wilson, a drug product manufacturing facility for cancer and neurology medicines expected to create up to 500 jobs, beside the $2 billion biologics campus it is already building there.
Health09/23/2026@HealthDesk
J&J Signs a Drug-Pricing Deal With Trump and Joins TrumpRx
Johnson & Johnson World Headquarters, 1 Johnson and Johnson Plaza, New Brunswick, New Jersey 08933, United StatesJohnson & Johnson
Starts 01/08/2026CONFIRMEDDate confidence: CONFIRMEDStated as firmHow firmly the source words the date: confirmed, scheduled, estimated, delayed or unverified.Show all CONFIRMED pins86% CONFIDENCEOverall confidence: 86%How well the pin's source and references back up its dates.Weighted average of how firmly 6 references, the source included, support the pin's start and end times; a reference counts half as much for every 180 days older than the newestShow all pins at 75% confidence or better272 days ago
J&J's release is datelined "New Brunswick, N.J. – JANUARY 8, 2026" and says the company "today announced a voluntary agreement with the Trump Administration"; coverage followed on 9 January.^[1]
Johnson & Johnson signed a voluntary most-favored-nation drug-pricing agreement with the Trump administration, selling medicines through TrumpRx.gov and to Medicaid at prices comparable to other developed countries in exchange for an exemption from pharmaceutical tariffs, and announced two new US plants in Pennsylvania and North Carolina.
Health09/23/2026@HealthDesk
J&J Announces Plan to Spin Off DePuy Synthes
Johnson & Johnson World Headquarters, 1 Johnson and Johnson Plaza, New Brunswick, New Jersey 08933, United StatesJohnson & Johnson
Starts 10/14/2025CONFIRMEDDate confidence: CONFIRMEDStated as firmHow firmly the source words the date: confirmed, scheduled, estimated, delayed or unverified.Show all CONFIRMED pins90% CONFIDENCEOverall confidence: 90%How well the pin's source and references back up its dates.Weighted average of how firmly 4 references, the source included, support the pin's start and end times; a reference counts half as much for every 180 days older than the newestShow all pins at 75% confidence or better358 days ago
The release is datelined "NEW BRUNSWICK, NJ, October 14, 2025 - Johnson & Johnson ... today announced the Company's intent to separate its Orthopaedics business"; it states no time of day (CNBC's^[3] report was up at 6:29 a.m. EDT and J&J's X post at 6:40 a.m. EDT), so the pin is the all-day 14 October.
Johnson & Johnson said it would separate its roughly $9.2 billion-a-year orthopaedics business into a standalone company called DePuy Synthes within 18 to 24 months, and named former Smith & Nephew chief Namal Nawana to run it.

111